Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

被引：0
|
作者：
Ashish Sharma
M. Hafeez Faridi
Nilesh Kumar
Nikulaa Parachuri
Rohini Sharma
Baruch D. Kuppermann
Francesco Bandello
Anat Loewenstein
Carl D. Regillo
机构：
[1] Lotus Eye Hospital and Institute,Department of Vitreoretina
[2] Chicago State University,College of Pharmacy
[3] The TIPS Global Institute,Department of Healthcare
[4] University of California,Gavin Herbert Eye Institute
[5] Scientific Institute San Raffaele,Department of Ophthalmology; University Vita
[6] Tel Aviv University,Salute
[7] Mid Atlantic Retina,Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine
来源：
Eye | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1008 / 1009
页数：1
相关论文
共 50 条
  • [41] An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
    Eldem, Bora
    Lai, Timothy Y. Y.
    Ngah, Nor Fariza
    Vote, Brendan
    Yu, Hyeong Gon
    Fabre, Alban
    Backer, Arthur
    Clunas, Nathan J.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 256 (05) : 963 - 973
  • [42] An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
    Bora Eldem
    Timothy Y. Y. Lai
    Nor Fariza Ngah
    Brendan Vote
    Hyeong Gon Yu
    Alban Fabre
    Arthur Backer
    Nathan J. Clunas
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256 : 963 - 973
  • [43] Real-World Treatment Patterns and Vision Outcomes with Ranibizumab for Diabetic Macular Edema
    Naujokaitis, Tadas
    Balciuniene, Vilma Jurate
    JOURNAL OF OPHTHALMOLOGY, 2021, 2021
  • [44] Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
    Popescu, Claudiu Costinel
    Mogosan, Corina Delia
    Enache, Luminita
    Codreanu, Catalin
    MEDICINA-LITHUANIA, 2022, 58 (12):
  • [45] Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
    Verma, Lalit
    Thulasidas, Mithun
    Purohit, Ajay
    Gupta, Avnindra
    Narula, Ritesh
    Talwar, Dinesh
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (02) : 347 - 351
  • [46] Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study
    Hamilton, Robin D.
    Clemens, Andreas
    Minnella, Angelo Maria
    Lai, Timothy Y. Y.
    Dai, Hong
    Sakamoto, Taiji
    Cheung, Chui Ming Gemmy
    Ngah, Nor Fariza
    Dunger-Baldauf, Cornelia
    Holz, Frank G.
    PLOS ONE, 2020, 15 (01):
  • [47] ONE YEAR REAL-WORLD OUTCOMES OF RANIBIZUMAB IN NAMD: INTERIM RESULTS FROM THE GLOBAL LUMINOUS STUDY
    Mitchell, Paul
    Gilhotra, Jagjit Singh
    Vote, Brendan
    Walsh, Meagan
    Woodcock, Chad
    Kurstjens, Nicol
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 : 12 - 12
  • [48] Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
    Holz, Frank G.
    Minnella, Angelo M.
    Tuli, Raman
    Yoganathan, Pradeepa
    Parikh, Soumil
    Hamilton, Robin
    PLOS ONE, 2020, 15 (12):
  • [49] Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
    Chang, Yi-Sheng
    Lee, Wan-Ju
    Lim, Chen-Chee
    Wang, Shih-Hao
    Hsu, Sheng-Min
    Chen, Yi-Chian
    Cheng, Chia-Yi
    Teng, Yu-Ti
    Huang, Yi-Hsun
    Lai, Chun-Chieh
    Tseng, Sung-Huei
    SCIENTIFIC REPORTS, 2018, 8
  • [50] Real-world outcomes of ranibizumab treatment in patients with retinal vein occlusion: the LUMINOUS™ study
    Pearce, Ian A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
12345